Piedmont Investment Advisors LLC lifted its holdings in Eli Lilly and Co (NYSE:LLY) by 26.4% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 314,414 shares of the company’s stock after purchasing an additional 65,602 shares during the quarter. Piedmont Investment Advisors LLC’s holdings in Eli Lilly and were worth $26,895,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other hedge funds have also bought and sold shares of LLY. Pathstone Family Office LLC increased its position in Eli Lilly and by 100.0% during the second quarter. Pathstone Family Office LLC now owns 58 shares of the company’s stock valued at $4,774,000 after acquiring an additional 29 shares during the last quarter. Vantage Financial Partners Ltd. Inc. purchased a new stake in Eli Lilly and during the second quarter valued at $494,000. Acrospire Investment Management LLC increased its position in Eli Lilly and by 16.7% during the second quarter. Acrospire Investment Management LLC now owns 1,399 shares of the company’s stock valued at $115,000 after acquiring an additional 200 shares during the last quarter. MPS Loria Financial Planners LLC purchased a new stake in Eli Lilly and during the second quarter valued at $128,000. Finally, San Francisco Sentry Investment Group CA purchased a new stake in Eli Lilly and during the second quarter valued at $129,000. Hedge funds and other institutional investors own 76.30% of the company’s stock.
In related news, major shareholder Lilly Endowment Inc sold 200,000 shares of the stock in a transaction that occurred on Wednesday, December 13th. The stock was sold at an average price of $88.20, for a total transaction of $17,640,000.00. Following the completion of the transaction, the insider now directly owns 123,084,104 shares of the company’s stock, valued at $10,856,017,972.80. The sale was disclosed in a filing with the SEC, which is available through this link. Also, SVP Susan Mahony sold 36,585 shares of the stock in a transaction that occurred on Monday, December 4th. The shares were sold at an average price of $86.18, for a total value of $3,152,895.30. Following the transaction, the senior vice president now directly owns 54,885 shares of the company’s stock, valued at $4,729,989.30. The disclosure for this sale can be found here. In the last ninety days, insiders sold 251,088 shares of company stock valued at $22,041,236. Corporate insiders own 0.20% of the company’s stock.
A number of analysts have commented on the company. Piper Jaffray Companies restated an “overweight” rating and issued a $105.00 price target (up previously from $103.00) on shares of Eli Lilly and in a research report on Friday, September 8th. Jefferies Group restated a “buy” rating and issued a $89.00 price target on shares of Eli Lilly and in a research report on Monday, September 11th. Morgan Stanley restated a “hold” rating and issued a $86.00 price target on shares of Eli Lilly and in a research report on Friday, September 15th. BMO Capital Markets restated a “sell” rating and issued a $71.00 price target on shares of Eli Lilly and in a research report on Thursday, September 28th. Finally, Cowen restated a “buy” rating and issued a $95.00 price target on shares of Eli Lilly and in a research report on Wednesday, October 4th. Three research analysts have rated the stock with a sell rating, seven have assigned a hold rating and nine have assigned a buy rating to the company. Eli Lilly and presently has a consensus rating of “Hold” and a consensus price target of $90.25.
Eli Lilly and Co (NYSE:LLY) opened at $85.52 on Friday. The firm has a market capitalization of $94,170.00, a PE ratio of 40.72, a PEG ratio of 1.59 and a beta of 0.35. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.38 and a quick ratio of 1.03. Eli Lilly and Co has a one year low of $74.00 and a one year high of $89.09.
Eli Lilly and (NYSE:LLY) last released its quarterly earnings data on Tuesday, October 24th. The company reported $1.05 earnings per share for the quarter, topping analysts’ consensus estimates of $1.03 by $0.02. The firm had revenue of $5.66 billion during the quarter, compared to analyst estimates of $5.52 billion. Eli Lilly and had a return on equity of 30.27% and a net margin of 9.90%. The business’s quarterly revenue was up 9.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.88 earnings per share. research analysts forecast that Eli Lilly and Co will post 4.22 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 9th. Stockholders of record on Thursday, February 15th will be paid a $0.5625 dividend. This is a positive change from Eli Lilly and’s previous quarterly dividend of $0.52. The ex-dividend date is Wednesday, February 14th. This represents a $2.25 dividend on an annualized basis and a dividend yield of 2.63%. Eli Lilly and’s dividend payout ratio is 99.05%.
ILLEGAL ACTIVITY WARNING: “Eli Lilly and Co (LLY) Stake Lifted by Piedmont Investment Advisors LLC” was first posted by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://transcriptdaily.com/2018/01/05/eli-lilly-and-co-lly-stake-lifted-by-piedmont-investment-advisors-llc.html.
Eli Lilly and Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Co (NYSE:LLY).
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.